Empowered Patient Podcast

Welcome to the Empowered Patient Podcast with Karen Jagoda. This show offers a glimpse into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the evolving dynamics in the medical and healthcare landscape. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations often focus on how technology is empowering providers, care facilities, pharmaceutical companies, and payers to improve patient outcomes and reduce friction across the healthcare landscape. Popular Topics Include: Virtual and digital health Use of AI, ML, and robots for clinical and administrative purposes Value-based healthcare Precision and stratified medicine Next-generation immuno, cell, and gene therapies Vaccines for infectious diseases and oncology Biomarkers and diagnostics Rare diseases MedTech and medical devices Clinical trials Population health Chronic conditions l Clinician and staff burnout Smart hospitals The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.

Localized Immunotherapy by Direct Injection Treats Solid Tumors and Activates the Immune System with Lew Bender Intensity Therapeutics TRANSCRIPT

Download PDF

Aug 5, 2026

Lew Bender, Founder and CEO of Intensity Therapeutics, has developed a novel approach to treating solid tumors through direct intratumoral injection of existing chemotherapy drugs. The company uses a proprietary formulation containing a special molecule that makes water-based drugs soluble in fatty tissue, allowing...

Localized Immunotherapy by Direct Injection Treats Solid Tumors and Activates the Immune System with Lew Bender Intensity Therapeutics

Aug 5, 2026

Transdermal Therapy Targets Acidity of Tumor Microenvironment to Enhance Immunotherapy Outcomes with Dr. Ryan Beal Dyve Biosciences TRANSCRIPT

Download PDF

Jul 22, 2026

Dr. Ryan Beal, Founder and CEO of Dyve Biosciences, has developed a transdermal delivery approach that uses the skin to deliver agents into circulation, where they selectively neutralize the acidic tumor microenvironment. By correcting acidity, the immune system is reactivated to better recognize and attack...

Transdermal Therapy Targets Acidity of Tumor Microenvironment to Enhance Immunotherapy Outcomes with Dr. Ryan Beal Dyve Biosciences

Jul 22, 2026

Multi-Target T Cell Engagers Transforming Treatment for Solid Tumors with Jack Silberstein Deck Bio TRANSCRIPT

Download PDF

Jul 16, 2026

Jack Silberstein, CEO of Deck Bio, is developing next-generation T cell engagers designed to activate the patient's immune system to shrink tumors. These T cell engagers are bispecific molecules that alert immune cells to recognize targets on cancer cells and kill them by binding to both the cancer cells and the T...